Search results for "lcsh:Diseases of the blood and blood-forming organs"

showing 2 items of 22 documents

Palliative splenic irradiation in primary and post PV/ET myelofibrosis: outcomes and toxicity of three radiation schedules

2009

Splenectomy and splenic irradiation (SI) are the sole treatment modalities to control drug resistant splenomegaly in patients with myelofibrosis (MF). SI has been used in poor surgical candidates but optimal total dose and fractionation are unclear. We retrospectively reviewed 14 MF patients with symptomatic splenomegaly. Patients received a median of 10 fractions in two weeks. Fraction size ranged from 0.2–1.4 Gy, and total dose varied from 2–10.8 Gy per RT course. Overall results indicate that 81.8% of radiation courses achieved a significant spleen reduction. Splenic pain relief and gastrointestinal symptoms reduction were obtained in 94% and 91% of courses, respectively. Severe cytopeni…

medicine.medical_specialtypalliationmedicine.medical_treatmentSplenectomyMyelofibrosisSpleenSubgroup analysisGastroenterologyArticleInternal medicineMedicinemyelofibrosis; splenomegaly; palliation; radiotherapy; low-dose irradiationMyelofibrosisAdverse effectradiotherapylow dose irradiationsplenomegalylcsh:RC633-647.5business.industrylow-dose irradiation.lcsh:Diseases of the blood and blood-forming organsHematologymedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureTolerabilityToxicitybusinessHematology Reports
researchProduct

Evaluation of the predictive value of the bleeding prediction score VTE‐BLEED for recurrent venous thromboembolism

2019

Abstract Introduction VTE‐BLEED is a validated score for identification of patients at increased risk of major bleeding during extended anticoagulation for venous thromboembolism (VTE). It is unknown whether VTE‐BLEED high‐risk patients also have an increased risk for recurrent VTE, which would limit the potential usefulness of the score. Methods This was a post hoc analysis of the randomized, double‐blind, placebo‐controlled PADIS‐PE trial that randomized patients with a first unprovoked pulmonary embolism (PE) initially treated during 6 months to receive an additional 18‐month of warfarin vs. placebo. The primary outcome of this analysis was recurrent VTE during 2‐year follow‐up after ant…

medicine.medical_specialtyrecurrencemedicine.drug_classvenous thromboembolismInternal medicinemedicineCumulative incidencecardiovascular diseasesanticoagulation therapylcsh:RC633-647.5business.industryAnticoagulantHazard ratioWarfarinlcsh:Diseases of the blood and blood-forming organsprediction scoreHematologyBleedbleedingequipment and suppliesmedicine.diseaseConfidence intervalPulmonary embolismDiscontinuationOriginal ArticlebusinessOriginal Articles: Thrombosismedicine.drugResearch and Practice in Thrombosis and Haemostasis
researchProduct